Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Microdosing and Meditation
NCT06560658Withdrawn
- Sponsor
- National University of Natural Medicine
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of psilocybin in major depressive disorder (MDD) (2 arms), sponsored by National University of Natural Medicine. Primary endpoints: Recruitment and Retention Feasibility at 1 year, Acceptability at 1 year and 1 more. Planned start Oct 2024; status: withdrawn.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06560658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560658.